Key Points
- Director Robert Malenka sold 21,262 shares on Jan. 29 at an average price of $18.55 for about $394,410, reducing his stake by 5.41% to 371,885 shares, per an SEC filing.
- Shares were trading down ~4.8% (opened $17.69); Maplight has a market cap of roughly $802.6M, a negative P/E (-0.48), and a 52‑week range of $12.24–$21.55.
- Maplight reported a major quarterly EPS miss — ($37.18) vs. consensus ($1.86) — while analysts are mixed, with a consensus "Moderate Buy" and an average price target of $31.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director Robert Malenka sold 6,612 shares of the company's stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $18.11, for a total transaction of $119,743.32. Following the transaction, the director owned 365,273 shares in the company, valued at $6,615,094.03. This represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Maplight Therapeutics Stock Performance
Shares of MPLT opened at $17.69 on Friday. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $21.55. The firm has a market cap of $802.60 million and a P/E ratio of -0.48. The company has a 50-day moving average price of $17.62.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last announced its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).
Wall Street Analyst Weigh In
MPLT has been the subject of a number of recent research reports. Zacks Research upgraded shares of Maplight Therapeutics to a "hold" rating in a research note on Monday, November 24th. Wall Street Zen raised shares of Maplight Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, December 20th. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an "outperform" rating and a $30.00 target price on the stock. Jefferies Financial Group started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a "buy" rating and a $32.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a "buy" rating and a $28.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $31.00.
Get Our Latest Analysis on MPLT
Maplight Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
